1013 ET - Centene's early share-price drop signals that reassuring words during its earnings call failed to soothe investors' worries about medical costs. The company stuck to its 2025 guidance but bumped up a measure of medical costs, and it flagged spending on high-cost drugs. Wall Street is concerned about the company's Medicaid business as well as the Affordable Care Act marketplace plans. Shares fall 7.3% to $57.10.(anna.mathews@wsj.com)
(END) Dow Jones Newswires
April 25, 2025 10:13 ET (14:13 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.